Mikrosatelliteninstabilität
Authors:
- 22 May 2019
- journal article
- research article
- Published by Springer Nature in Der Pathologe
- Vol. 40 (3) , 313-327
Abstract
Mit Begründung des Bethesda-Mikrosatelliten-Testpanels war der Nachweis von Mikrosatelliteninstabilität (MSI) bzw. der zugrunde liegenden Mismatch-Reparaturgen-Defizienz (MMRD) Bestandteil des Screenings auf erbliches Lynch-Syndrom (LS, vormals HNPCC). Neuerdings ist MSI/MMRD zu einem wichtigen Biomarker zur Vorhersage des Therapieerfolgs moderner Checkpointimmuntherapien geworden. Die MSI-Analyse erfolgt mittels Polymerase-Kettenreaktion (PCR) mit und ohne Fragmentlängenbestimmung und Next Generation Sequencing (NGS). Für den MMRD-Nachweis stehen immunhistochemische Methoden zur Verfügung. Bezogen auf einzelne Tumorentitäten kommen diese Testverfahren unterschiedlich zur Anwendung. Aktuell ist MSI/MMRD ein Biomarker mit sehr breitem Indikationsspektrum in der Tumorpathologie vor allem beim Kolorektal‑, Endometrium- und Magenkarzinom. Bei fortgeschrittenen Karzinomen ist MSI ein etablierter Parameter zur Prädiktion der Therapieresponse checkpointgerichteter Immuntherapien. After introduction of the Bethesda microsatellite test panel demonstration of microsatellite instability (MSI) and/or loss of mismatch repair proteins (MMRD) was primarily used as a marker for cancer predisposition of Lynch syndrome (LS, previous: HNPCC). Nowadays MSI/MMRD has become an important biomarker to predict therapy response to checkpoint immunotherapies. MSI can be determined either by polymerase chain reaction (PCR)-based technologies with or without specification of fragment sizes or next generation sequencing (NGS) methods. Depending on the individual tumor entities, these test methods are used differently. Currently, MSI/MMRD is a tumor biomarker which covers a broad spectrum of indications in tumor pathology, especially in colorectal, endometrial and gastric cancer. In advanced carcinomas, MSI is an established predictor of therapy response to checkpoint-directed immunotherapies.Keywords
This publication has 34 references indexed in Scilit:
- Update on Lynch syndrome genomicsFamilial Cancer, 2016
- Deficient mismatch repair: Read all about it (Review)International Journal of Oncology, 2015
- Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancerGut, 2015
- Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapyBMC Cancer, 2015
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS StudiesClinical Cancer Research, 2014
- Microsatellite Instability Detection by Next Generation SequencingClinical Chemistry, 2014
- MSIsensor: microsatellite instability detection using paired tumor-normal sequence dataBioinformatics, 2013
- MikrosatelliteninstabilitätDer Pathologe, 2010
- Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancerInternational Journal of Cancer, 2005
- Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCRGastroenterology, 2002